GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » Net-Net Working Capital

CellSource Co (TSE:4880) Net-Net Working Capital : 円212.12 (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CellSource Co Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

CellSource Co's Net-Net Working Capital for the quarter that ended in Jan. 2024 was 円212.12.

The industry rank for CellSource Co's Net-Net Working Capital or its related term are showing as below:

TSE:4880's Price-to-Net-Net-Working-Capital is ranked worse than
63.02% of 914 companies
in the Biotechnology industry
Industry Median: 4.235 vs TSE:4880: 6.42

CellSource Co Net-Net Working Capital Historical Data

The historical data trend for CellSource Co's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co Net-Net Working Capital Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Net-Net Working Capital
Get a 7-Day Free Trial 74.26 91.34 111.69 156.06 229.22

CellSource Co Quarterly Data
Oct18 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 162.35 170.13 162.87 229.22 212.12

Competitive Comparison of CellSource Co's Net-Net Working Capital

For the Biotechnology subindustry, CellSource Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellSource Co's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where CellSource Co's Price-to-Net-Net-Working-Capital falls into.



CellSource Co Net-Net Working Capital Calculation

CellSource Co's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Oct. 2023 is calculated as

Net-Net Working Capital(A: Oct. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(4781.022+0.75 * 364.279+0.5 * 305.925-677.739
-0-0)/19.7605
=229.22

CellSource Co's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2024 is calculated as

Net-Net Working Capital(Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(4678.757+0.75 * 324.238+0.5 * 251.833-846.642
-0-0)/19.8055
=212.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


CellSource Co  (TSE:4880) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


CellSource Co Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of CellSource Co's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


CellSource Co (TSE:4880) Business Description

Traded in Other Exchanges
N/A
Address
Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines